北京若生智能科技有限公司
Drug Database
AV

avapritinib

✓ Approved

Genetron Health · PDGFRA · 辅助诊断

什么是 avapritinib？

avapritinib 是一种辅助诊断，由Genetron Health研发。该药已获批，用于治疗相关适应症，给药途径：Others。

药物档案

公司Genetron Health
药物类别辅助诊断
分子靶点PDGFRA
给药途径Others
状态Approved
来源： ClinicalTrials.gov, Genetron Health

作用机制

分子靶点

avapritinib 作用于 1 个分子靶点：

PDGFRAplatelet derived growth factor receptor alpha (PDGFR-2, CD140A)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

avapritinib 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

相关研究文献

PubMedIssues in mental health nursing2026-09-10

Person Mapping and Tier-Class Symptom Status: A Framework for Collaborative Mental Health Assessment Across Clinical Settings.

Tallman Samantha B SB

Mental health symptoms are encountered across virtually every healthcare setting, yet assessment often occurs under conditions of diagnostic uncertainty, time constraints, and evolving clinical presentations. Although diagnostic classification systems provide an essential shared language for communication, treatment planning, and reimbursement, clinicians often require additional approaches to organize symptom information, assess functional impact, communicate clinical risk, and support person-centered care prior to diagnostic stabilization. This paper proposes two complementary conceptual frameworks: **Person Mapping** and **Tier-Class Symptom Status**. Person Mapping is a longitudinal formulation framework that organizes current symptoms, functional impact, developmental and trauma history, sociocultural context, strengths, worldview, and patient-defined goals. Tier-Class Symptom Status complements this process by describing current mental health status through dimensional severity tiers and primary symptom domains. Together, the frameworks provide a structured yet flexible approach to supporting symptom-based assessment, interdisciplinary communication, continuity of care, longitudinal monitoring, and stepped-care decision-making without requiring immediate categorical diagnosis. They are intended to complement, rather than replace, established diagnostic systems while promoting ethical, person-centered assessment across clinical settings. Future research should evaluate the feasibility, reliability, clinical utility, and outcomes associated with implementation across diverse practice environments.

PMID 42720671
阅读全文 →
PubMedAnnals of translational medicine2026-09-10

Individualized pharmacotherapy: background and development.

Jørgensen Jan Trøst JT, Westergaard Niels N

Most drug prescriptions are still based on empiricism and not on solid biological data, which often results in considerable patient variability and, sometimes, low patient benefits. Although variability in patient response to pharmacotherapy has long been recognized, only in recent decades have new molecule analytical methods provided insight into some of the causes, which are often related to somatic or germline genetic variations. Based on this insight, different predictive biomarker tests have been developed to optimize and individualize pharmacotherapy. These biomarker tests are classified as companion diagnostic (CDx) or pharmacogenetic (PGx) tests. In both the United States and Europe, CDx and PGx information is part of the regulatory drug labeling and is included in the Prescribing Information for the individual drugs and biologics. In the United States, this type of information is found in the labeling of more than 400 regulatory-approved drugs and biological products. Despite these measures and the documented clinical utility of CDx and PGx testing, clinical implementation is lagging, especially with regard to PGx. There are various reasons for the lack of testing, such as insufficient education and awareness among healthcare professionals, inadequate access to biomarker testing, regulatory hurdles, and insufficient reimbursements. Although progress has been made in recent years, further efforts are needed to fully realize the potential of individualized pharmacotherapy by integrating the use of predictive biomarkers into routine clinical practice.

PMID 42718847
阅读全文 →
PubMedCureus2026-09-10

Comparative Diagnostic Accuracy of Clinical Pallor at Different Anatomical Sites for Detecting Anemia in Pregnant Women Using HemoCue® as the Reference Standard.

Jegadeesan Dhivagar D, Rajendran Vijaykumar V, Rajamanickam Saranya S

Background Anemia during pregnancy remains a major public health problem in low-resource settings. Although hemoglobin estimation using portable devices such as the HemoCue® Hb 201 System (HemoCue AB, Ängelholm, Sweden) is reliable, clinical assessment of pallor continues to be widely used in primary care because of its simplicity, feasibility, and low cost. However, evidence comparing the diagnostic accuracy of pallor at different anatomical sites among pregnant women is limited. Objective This study aimed to determine and compare the diagnostic accuracy of clinical pallor at different anatomical sites for detecting anemia among pregnant women using HemoCue® hemoglobin estimation as the reference standard. Methods A cross-sectional diagnostic accuracy study was conducted among 186 pregnant women attending the Rural Health Training Centre (RHTC) in Barwala, Delhi. Clinical pallor was assessed under natural light at the palpebral conjunctiva, nail bed, palm, and palmar crease. Hemoglobin concentration was measured using HemoCue® as the reference standard. Diagnostic accuracy measures, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), likelihood ratios, and Cohen's kappa (κ), were calculated for detecting anemia (hemoglobin <11 g/dL). Results Among the 186 pregnant women enrolled, 139 (74.7%) were anemic based on HemoCue® hemoglobin estimation. Palpebral conjunctival pallor demonstrated the highest sensitivity (98.6%) and specificity (93.6%), with excellent agreement (κ = 0.92). Nail bed pallor showed a sensitivity of 81.3% and a specificity of 42.6%, while palmar pallor demonstrated a sensitivity of 71.9% and a specificity of 78.7%. Palmar crease pallor had the lowest sensitivity (46.0%) but a specificity of 78.7%. Palpebral conjunctival pallor also showed the highest positive LR (LR+; 15.45) and the lowest negative LR(LR-; 0.02). Conclusion Palpebral conjunctival pallor demonstrated the highest diagnostic accuracy for detecting anemia in pregnant women and may serve as a reliable screening method in primary care settings where hemoglobin estimation is unavailable. Palm and palmar crease examination may provide complementary clinical information but are less accurate than conjunctival assessment.

PMID 42719886
阅读全文 →
PubMedAge and ageing2026-09-10

Culturally adapted post-diagnostic dementia support for South Asian people living with dementia and caregivers: a rapid review.

Akhtar Amirah A, Nwofe Emmanuel E, Dodd Emily E, Fry Gary G et al.

The number of minority ethnic people living with dementia (PLWD) in the UK is predicted to rise to 50 000 by 2026 and 172 000 by 2051. As the global population ages, there is a greater need to develop culturally appropriate post-diagnostic support for PLWD from minority ethnic backgrounds. A rapid review was conducted of culturally adapted post-diagnostic dementia support for South Asian people with dementia and carers. Eight electronic databases were searched from inception until 16 September 2025. Databases included Cumulative Index to Nursing and Allied Health Literature, Excerpta Medica Database, MEDical Literature Analysis and Retrieval System Online, Psychological Information, Turning Research Into Practice, Allied and Complementary Medicine Database, Social Policy and Practice and the Cochrane Database of Systematic Reviews. Two reviewers independently screened the studies. Consistent with rapid review methods, no formal quality assessment of included studies was undertaken. The rapid review adhered to Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. Twelve studies were included. These included seven carer support programmes focusing on raising awareness and education on dementia and care. These interventions increased carers' knowledge of dementia and confidence in caregiving. Four studies reported on psychosocial interventions: Cognitive Stimulation Therapy, Cognitive Behaviour Therapy and Meditation Therapy, demonstrating benefits for caregiver burden and mental health. One study reported on service-level innovations through a South Asian link nurse, which improved access to services and facilitated the development of culturally appropriate information materials. The findings of this rapid review demonstrate the feasibility and perceived value of culturally sensitive psychoeducation, carer training and psychosocial interventions. However, research remains small-scale, methodologically limited, with little focus given to interventions directly supporting PLWD.

PMID 42720437
阅读全文 →
PubMedExperimental biology and medicine (Maywood, N.J.)2026-09-10

Altered serum interleukin-4 and monocyte chemoattractant protein-3 levels are associated with generalized anxiety disorder: a case-control study.

Binta Rashid Most Humayra MH, Islam Mehedi M, Ashraful Islam Sardar Mohammad SM, Islam Md Rabiul MR

Generalized Anxiety Disorder (GAD) is a long-term mental health condition often associated with immune system dysregulation. While pro-inflammatory and anti-inflammatory cytokines are known to influence neuroinflammation, their specific roles in GAD remain less understood. This study investigates the relationship between serum levels of IL-4 and MCP-3 and GAD in a Bangladeshi population. This case-control study included 44 patients with GAD and 44 healthy controls (HCs). Participants were examined using the GAD-7 scale. Serum IL-4 and MCP-3 levels were measured using ELISA. Data were analyzed using t-tests, Spearman's correlation, and Receiver Operating Characteristic (ROC) curve analysis to assess diagnostic performance. GAD patients had significantly lower serum IL-4 levels (11.82 ± 10.91 pg/mL) and higher MCP-3 levels (57.80 ± 19.85 pg/mL) compared to HCs (IL-4: 24.51 ± 15.36 pg/mL; MCP-3: 34.01 ± 15.75 pg/mL; p < 0.001). IL-4 levels showed a significant negative correlation with GAD-7 scores (r = -0.496, p < 0.001), while MCP-3 showed a positive correlation (r = 0.544, p < 0.001). ROC analysis indicated that MCP-3 had higher diagnostic accuracy (AUC = 0.848, sensitivity = 87.6%, specificity = 84.3%) compared to IL-4 (AUC = 0.782, sensitivity = 80.2%, specificity = 78.5%). Moreover, decreased IL-4 and elevated MCP-3 levels were found to be significantly associated with GAD severity, suggesting an immune imbalance. These cytokines may serve as promising diagnostic biomarkers and therapeutic targets for GAD. Further longitudinal studies are recommended to investigate this causal relationship and its underlying mechanisms.

PMID 42719764
阅读全文 →
PubMedCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026-09-10

Associations Between Pre-diagnostic Plasma Metabolites and Ovarian Cancer: A Prospective Case-Cohort Analysis in the Cancer Prevention Study-3.

Pfluger Brigitte A BA, Masters Matthew M, Nguyen Nancy B NB, Patel Alpa V AV et al.

Ovarian cancer remains a significant health concern among U.S. women, yet its underlying etiology is not fully understood. Untargeted metabolomics enables comprehensive profiling of small molecules that may provide insight into metabolic alterations associated with ovarian cancer risk. We conducted a case-cohort study within the Cancer Prevention Study-3, measuring pre-diagnostic plasma metabolites via untargeted metabolomics in 127 ovarian cancer cases and a randomly selected sub-cohort of 1,811 women, one of whom was later diagnosed with ovarian cancer. Median follow-up time was 2.4 years (IQR: 1.2-3.6) among ovarian cancer cases and 3.2 years (IQR: 2.5-5.2) in the sub-cohort. Metabolite associations with ovarian cancer risk were estimated using multivariable Prentice-weighted Cox models, and pathway enrichment analyses were performed. False discovery rate (FDR) correction was applied, considering FDR < 0.2 statistically significant. Among 868 plasma metabolites analyzed, none showed statistically significant associations with ovarian cancer risk after FDR correction. In stratified analyses by menopausal status, five metabolites remained statistically significant after FDR correction among postmenopausal women only. Pathway enrichment analyses identified several lipid-related sub-pathways enriched among metabolites associated with ovarian cancer risk (FDR-adjusted p-value < 0.2), with the strongest positive enrichment observed for primary bile acid metabolism and the strongest negative enrichment for sphingomyelins. In this prospective metabolomics analysis, individual pre-diagnostic plasma metabolites were not associated with ovarian cancer risk, but lipid-related pathways and possible differences by menopausal status may warrant additional investigation. These findings contribute to the growing untargeted metabolomics literature on ovarian cancer.

PMID 42720260
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多avapritinib